1.      Joish VN, Boklage S, Lynen R, Schmidt A and Lin J. Use of drospirenone/ethinyl estradiol (DRSP/EE) among women with acne reduces acne treatment–related resources.  Accepted by Journal of Medical Economics

2.      Pineo G, Lin J, Stern L, Subrahmanian T and Annemans L. The Economic Impact of Enoxaparin Versus Unfractionated Heparin for Venous Thromboembolism Prophylaxis in Patients with Acute Ischemic Stroke: A Hospital Perspective of the PREVAIL Trial.  Accepted by Journal of Hospital Medicine.

3.      Amin AN, Lin J, Thompson S, and Wiederkehr D. Inpatient and Outpatient Occurrence of Deep-Vein Thrombosis and Pulmonary Embolism and Thromboprophylaxis in US Patients Following Selected At-Risk Surgeries.  Accepted by Annals of Pharmacotherapy.

4.      Amin AN, Lin J, Thompson S and Wiederkehr D. Real-World Rates of Inhospital and Post-Discharge Deep-Vein Thrombosis and Pulmonary Embolism in At-Risk Medical Patients in the US.  Accepted by Clinical and Applied Thrombosis/Hemostasis.

5.      Deitelzweig SB, Lin J and Lin G. Preventing Venous Thromboembolism Following Orthopedic Surgery: Analysis of Special Populations in the US Who May Require Alterations to Anticoagulant Regimens. Clin Appl Thromb Hemost. 2011 May.

6.      Merli GJ, Malangone E, Lin J, Lamerato L, Stern L. Real-world practices to prevent venous thromboembolism with pharmacological prophylaxis in US orthopedic surgery patients: An analysis of an integrated healthcare database.  J Thromb Thrombolysis. 2011 Jul;32(1):89-95.

7.      Amin A, Lenhart G, Princic N, Lin J, Thompson S and Johnston S. Retrospective Administrative Database Study of the Time Period of Venous Thromboembolism Risk During and Following Hospitalization for Major Orthopedic or Abdominal Surgery in Real-World US Patients. Hosp Pract (Minneap). 2011 Apr;39(2):7-17.

8.      Deitelzweig SB, Johnson BH, Lin J, and Schulman KL. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol. 2011 Feb;86(2):217-20.

9.      Deitelzweig SB, Johnson BH, Lin J, and Schulman KL. Venous thromboembolism in the US: does race matter? J. Thromb Thrombolysis. 2011 Feb; 31(2):133-8.

10.   Pineo G, Lin J, Stern L, Subrahmanian T and Annemans L. Economic Impact of Enoxaparin after Acute Ischemic Stroke Based on PREVAIL. Clinical and Applied Thrombosis/Hemostasis. 2011 Apr;17(2):150-7.

11.   Deitelzweig S., Lin J., Kreilick C., Hussein M., Battleman D. Warfarin Therapy in Patients with Venous Thromboembolism: Patterns of Use and Predictors of Clinical Outcomes. Advances in Therapy. 2010 Sep;27(9):623-33. Epub 2010 Jul 30.

12.   Kim MH, Lin J, Foltz Boklage SH and Kreilick CA. Total costs and atrial fibrillation ablation success or failure in Medicare-aged patients in the US. Advances in Therapy. 2010 Sep;27(9):600-12. Epub 2010 Aug 9.

13.   Deitelzweig S, Lin J, Hussein M and Battleman D.  Are surgical patients at risk of venous thromboembolism currently meeting the Surgical Care Improvement Project performance measure for appropriate and timely prophylaxis?  Journal of Thrombosis and Thrombolysis. 2010 Jul;30(1):55-66.

14.   Naccarelli GV, Johnson SS, Lin J, Patel PP and Schulman KL. Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA-Like Patients with Atrial Fibrillation/Atrial Flutter in the United States. Clinical Cardiology 2010 May;33(5):270-9

15.   Amin, AN, Lin J, Johnson BH and Schulman KL. Clinical and economic outcomes with appropriate or partial prophylaxis. Thrombosis Research, 2010 Jun;125(6):513-517.

16.   Amin AN, Lin J and Ryan A. Lack of Thromboprophylaxis Across the Care Continuum in US Medical Patients.  Hospital Practice (Minneap). 2010 Jun;38(3):17-25.

17.   Zimetbaum, PJ, Thosani A, Yu H, Xiong Y, Lin J, Kothawala P and Emons M.  Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? American Journal of Medicine, 2010 May;123(5):446-53.

18.   Merli G, Ferrufino CP, Lin J, Hussein M, Battleman D. Hospital-based Costs Associated with Venous Thromboembolism Prophylaxis Regimens.  J Thrombosis & Thrombolysis, 2010 May;29(4):449-58.

19.   Amin AN, Lin J and Ryan A. Need to Improve Thromboprophylaxis Across the Continuum of Care for Surgical Patients.  Advances in Therapy, 2010 Feb;27(2):81-93.

20.   Kim MH, Lin J, Hussein M, Kreilick C and Battleman DS. Cost of atrial fibrillation in United States managed care organizations. Advances in Therapy. 2009 Sep;26(9):847-57

21.   Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing Prevalence Of Atrial Fibrillation And Flutter In The United States. American Journal of Cardiology. 2009 Dec 1;104(11):1534-9.

22.   Kim MH, Klingman D, Lin J, Battleman DS.  Patterns and Predictors of Discontinuation of Rhythm-Control Therapy in Patients with Newly-Diagnosed Atrial Fibrillation.  Pharmacotherapy. 2009 Dec;29(12):1417-26.

23.   Kim MH, Lin J, Hussein M and Battleman D. Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy. Current Medical Research and Opinion. 2009 Dec;25(12):3037-47.

24.   Ishak J., Proskorovsky I., Guo S., Lin J., Caro J. Persistence with anti-arrhythmics and its impact on atrial fibrillation-related outcomes.  American Journal of Pharmacy Benefits. 2009;1(4):193-200.

25.   Kim MH, Lin J and Kreilick C. National Assessment of Medicare Prescription-Plan Coverage Gaps Among Atrial Fibrillation Patients in the United States.  Advances in Therapy. 2009 Aug;26(8):784-94.

26.   Spyropoulos AC, Hussein M, Lin J, Battleman D. Rates of symptomatic venous thromboembolism in US surgical patients: a retrospective administrative database study.  Journal of Thrombosis and Thrombolysis. 2009 Nov;28(4):458-64.

27.   Spyropoulos AC, Hussein M, Lin J, Battleman D. Rates of venous thromboembolism occurrence in medical patients among the insured population. Thrombosis and Haemostasis. 2009 Nov;102(5):951-7.

28.   Amin, AN, Lin J, Lenhart G, Schulman KL. Clinical and economic outcomes in patients at risk for venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.  Thrombosis and Haemostasis. 2009 Aug;102(2):321-6.

29.   Amin, A.N., Stemkowski, S., Lin, J. and Yang, G. Thromboprophylaxis use in US Hospitals: Adherence to the Seventh American College of Chest Physician’s Recommendations for At-Risk Medical and Surgical Patients.  Journal of Hospital Medicine. 2009 Oct;4(8):E15-21

30.   Amin AN, Lin J, Yang G and Stemkowski S. Are there any differences in the clinical and economic outcomes between US cancer patients receiving appropriate or inappropriate VTE prophylaxis? Journal of Oncology Practice . Vol 5, No 4 (July), 2009: 159-164.

31.   Kim, M.H., Lin, J., Hussein, M. and Battleman, D. Incidence and temporal pattern of hospital readmissions for patients with atrial fibrillation. Current Medical Research and Opinion, May 2009, Vol. 25, No. 5, 1215-1220.

Accompanied by an Editorial Commentary: Burden of atrial fibrillation. Chee W. Khoo and, Gregory Y. H. Lip Current Medical Research and Opinion, May 2009, Vol. 25, No. 5, 1261-1263

32.   Kim, M., Klingman, D., Lin, J., Pathak, P., and Battleman, D. Cost of Hospital Admission for Antiarrhythmic Drug Initiation in Atrial Fibrillation in the United States, Annals of Pharmacotherapy. 2009 May; 43(5):840-8.

33.   Amin, A., Stemkowski, S., Lin, J. and Yang, G. Appropriate thromboprophylaxis in hospitalized cancer patients. Clinical Advances in Hematology & Oncology, Vol. 6, Issue 12, Dec 2008: 910-920.

34.   Baroletti S., Piovella C., Fanikos J., Labreche M., Lin J., Goldhaber S.Z. Heparin-induced thrombocytopenia (HIT): Clinical and economic outcomes. Thrombosis and Haemostasis 2008, 100 6: 1130-1135.

35.   Deitelzweig S., Becker R., Lin J., Benner J.  Comparison of the 2-year clinical and economic outcomes of VTE prophylaxis options in medical patients at risk of VTE. Thrombosis and Haemostasis, 2008 100 5: 810-820.

36.   Merli, G., Ferrufino, C., Lin, J., Hussein, M., Battleman, D. Hospital-based costs associated with VTE treatment regimens. Journal of Thrombosis and Haemostasis, 2008 Jul; 6(7):1077-86.

37.   Amin, A., Stemkowski, S., Lin, J. and Yang, G. Preventing venous thromboembolism in US hospitals: are surgical patients receiving appropriate prophylaxis? Thrombosis and Haemostasis, Apr 2008; 99(4):796-7.  

38.   Spyropoulos, A.C. and Lin, J.  Direct Medical Costs of Venous Thromboembolism and Subsequent Hospital Readmission Rates: An Administrative Claims -- Analysis From 30 Managed Care Organizations, Journal of Managed Care Pharmacy, Aug. 2007, Vol 13, Issue 6, 475-486.

39.   Amin, A., Stemkowski, S., Lin, J. and Yang, G.  Thromboprophylaxis rates in US medical centers: success or failure? Journal of Thrombosis and Haemostasis, Aug. 2007 - Vol. 5 Issue 8, 1610–1616.

Accompanied by an editorial comment: Goldhaber SZ. Preventing pulmonary embolism and deep vein thrombosis: a 'call to action' for vascular medicine specialists. J Thromb Haemost. 2007 Aug;5(8):1607-9.

40.   Yu. H.T., Dylan, M.L., Lin, J., and Dubois, R.W. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. American Journal of Health-system Pharmacy. 2007 Jan 1;64(1):69-76.

41.   MacDougall, D.A., Feliu, A.L., Boccuzzi, S.J. and Lin, J. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome.  American Journal of Health-system Pharmacy, 2006; Volume 63.

42.   Morgan, K.T., Jayyosi, Z., Hower, M.A., Pino, M.V., Connolly, T.M., Kotlenga, K., Lin, J., Wang, M., Schmidts, H., Bonnefoi, M., Elston, T.C. and Boorman, G.A. The hepatic transcriptome as a window on whole-body physiology and pathophysiology. Toxicologic Pathology, 2005;33(1):136-45.

43.   Cao W., Epstein C., Liu H., DeLoughery C., Ge N., Lin J., Diao R., Cao H., Long F., Zhang X., Chen Y., Wright P.S., Busch S., Wenck M., Wong K., Saltzman A.G., Tang Z., Liu L., Zilberstein A.. Comparing gene discovery from Affymetrix GeneChip microarrays and Clontech PCR-select cDNA subtraction: a case study.  BioMedCentral Genomics 2004 May 26.

44.   Lim, A., Dimalanta, E.T., Potamousis, K.D., Yen, G., Apodoca, J., Tao, C., Lin, J., Qi, R., Skiadas J., Ramanathan, A., Perna, N.T., Plunkett, G. 3rd, Burland, V., Mau, B., Hackett, J., Blattner F.R., Anantharaman, T.S., Mishra, B., Schwartz, D.C. Shotgun optical maps of the whole Escherichia coli O157:H7 genome. Genome Research 2001 Sep; 11(9):1584-93.

45.   Perna, N.T., Plunkett, G., Burland, V., Mau, B., Glasner, J.D., Rose, D.J., Mayhew, G.F., Evans, P.S., Gregor, J., Kirkpatrick, H.A., PoÂsfai, G., Hackett, J., Klink, S., Boutin, A., Shao, Y., Miller, L., Grotbeck, E.J., Davis, N.W., Lim, A., Dimalanta, E.T., Potamousis, K.D., Apodaca, J., Anantharaman, T.S., Lin, J., Yen, G., Schwartz, D.C., Welch, R.A. and Blattner, F.R. Genome sequence of enterohaemorrhagic Escherichia coli O157:H7, Nature, 2001 Jan; 409:529-533

46.   Lin, J., Qi, R., Aston, C., Jing, J., Anantharaman, T.S., Mishra, B., White, O., Daly, M.J., Minton, K.W., Venter, J.C., Schwartz, D.C.  Whole-genome shotgun optical mapping of Deinococcus radiodurans, Science, 1999 Sep; 285(5433):1558-62

47.   Jing, J., Lai, Z., Aston, C., Lin, J., Carucci, D.J., Gardner, M.J., Mishra, B., Anantharaman, T.S., Tettelin, H., Cummings, L.M., Hoffman, S.L., Venter, J.C. and Schwartz, D.C.  Optical mapping of plasmodium falciparum chromosome 2, Genome Research, 1999 Feb; 9(2):175-81

48.   Wang, W., Lin, J. and Schwartz, D.C.  Scanning Force Microscopy of Fluid Flow elongated DNA molecules, Biophysical Journal, 1998 Jul; 75(1): 513-520